Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum
Autor: | Yutaka Yamamoto, Aiko Sueta, Lisa Goto-Yamaguchi, Takashi Takeshita, Shi Qui, Hirotaka Iwase, Kaori Hidaka, Mai Tomiguchi, Ikuko Suzu |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Adult medicine.medical_specialty genetic structures DNA Copy Number Variations medicine.drug_class Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms In situ hybridization Monoclonal antibody Gastroenterology 03 medical and health sciences 0302 clinical medicine Breast cancer Surgical oncology Internal medicine Extracellular Biomarkers Tumor Medicine Humans Pharmacology (medical) Radiology Nuclear Medicine and imaging skin and connective tissue diseases neoplasms Chemotherapy medicine.diagnostic_test business.industry General Medicine Middle Aged medicine.disease Extracellular Matrix 030104 developmental biology Oncology 030220 oncology & carcinogenesis Immunoassay Immunohistochemistry Female business Cell-Free Nucleic Acids |
Zdroj: | Breast cancer (Tokyo, Japan). 28(3) |
ISSN: | 1880-4233 |
Popis: | HER2 (human epidermal growth factor receptor 2) status has been evaluated in breast cancer (BC) tissues by immunohistochemistry or in situ hybridization. We evaluated HER2 copy number (CN) assay in plasma cell-free DNA (cfDNA) from blood samples and compared it with protein measurements of HER2 extracellular domain (ECD) in serum. Serum HER2-ECD levels were measured by chemi-luminescence immunoassay using anti-HER2 monoclonal antibodies. Analyses were performed on 120 cases of primary BC, 30 cases of metastatic BC and 34 cases treated by neoadjuvant chemotherapy (NAC). This study was approved by Medical Research Review Advancement No. 1857 for Kumamoto University. There was a positive correlation between HER2-CN ratios and HER2-ECD levels, in primary (n = 54) and metastatic (n = 30) HER2-positive BC (P = 0.003 and P |
Databáze: | OpenAIRE |
Externí odkaz: |